Zobrazeno 1 - 10
of 4 964
pro vyhledávání: ''
Autor:
Li Zhu, Shuning Ding, Ou Huang, Weiguo Chen, Yafen Li, Weilin Chen, Xiaosong Chen, Jiayi Wu, Mengdi Chen, Caijin Lin, Deyue Liu, Kunwei Shen, Lisa Andriani, Jianrong He
Publikováno v:
Clinical Breast Cancer. 22:e147-e156
BACKGROUND In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, emerging evidence imply that clinical behaviors differ according to hormone receptor (HR) status. However, there is no conclusion about the relevance between estrog
Autor:
C. Meyer, Y. Fouché, Emmanuel Chamorey, M. Dejode, C. Bailleux, J. Haudebourg, Renaud Schiappa, Y. Delpech, Emmanuel Barranger
Publikováno v:
Clinical Breast Cancer. 22:121-126
Background Delays in initiating adjuvant chemotherapy after breast cancer surgery seems to have an impact on patients’ risk of relapse and their survival rate. The aim of this retrospective study was to identify factors delaying initiation of adjuv
Autor:
Ashley J. Schlafstein, Karen D. Godette, Shannon Kahn, Mylin A. Torres, Subir Goyal, Jolinta Lin, Trevor J. Royce, Sagar A. Patel, Yuan Liu
Publikováno v:
Clinical Breast Cancer. 22:127-135
Neoadjuvant chemotherapy (NAC) is increasingly used for operable breast cancer (BC). Appropriate radiation therapy (RT) fields (ie, whole breast [WB] ± regional nodal irradiation [RNI]) in patients who were clinically node positive (cN1) but convert
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 112:40-51
The omission of radiation therapy (RT) in older women with stage 1 estrogen-receptor-positive (ER+) breast cancer receiving endocrine therapy (ET) is an acceptable strategy based on randomized trial data. Less is known about the omission of ET with o
Publikováno v:
Clinical Breast Cancer. 22:e91-e100
Multiple factors influence the time elapsed between diagnosis of breast cancer and surgical extirpation of the primary tumor. The disease-free interval between resection of primary breast cancer and first evidence of recurrence is predictive of morta
Autor:
Ning Zhang, Jun Zhou, Li Mei, Jie Tan, Qianzhi Chen, Yuyin Liu, Ming Xu, Shengnan Ruan, Peng-Fei Yi
Publikováno v:
Clinical Breast Cancer
The coronavirus disease 2019 (COVID-19) pandemic is a global public health event. Wuhan used to be the epicenter of China and finally controlled the outbreak through city lockdown and many other policies. However, the pandemic and the prevention stra
Autor:
Carol Tweed, Nicholas Huerta, Lorraine Tafra, Rubie Sue Jackson, Charles Mylander, Martin Rosman, Laura Martino, Kip Waite, Elaine Lee
Publikováno v:
Clinical Breast Cancer. 21:e731-e737
Introduction With the advent of genomic assays, sentinel lymph node biopsy (SLNB) may be less impactful in determining adjuvant breast cancer therapy. We evaluated the influence of SLNB on adjuvant therapy recommendation when the Oncotype DX recurren
Autor:
Tawfiqul Bhuiya, Juan P. Idrovo, Jin Cao, Pooja Navale, Louis J. Auguste, Sudarshana Roychoudhury, Silvat Sheikh-Fayyaz, Hua Guo
Publikováno v:
Clinical Breast Cancer. 21:e638-e646
This study explored human papillomavirus (HPV) amplification in breast benign and malignant lesions by chromogenic in situ hybridization (CISH) and the concordance of p16 expression by immunohistochemistry.The presence of HPV6/11 and HPV16/18 in 33 c
Autor:
Larisa M. Haupt, Gabrielle Bradshaw, K.M. Taufiqul Arif, Rachel K. Okolicsanyi, Philippa H. Youl, Robert A. Smith, Thanh Tan Nguyen, Lyn R. Griffiths
Publikováno v:
Clinical Breast Cancer. 21:e694-e703
Introduction Breast cancer (BC), a heterogeneous disease, features microRNA-related single nucleotide polymorphisms (miRSNPs) as underlying factors of BC development, thus providing targets for novel diagnostic and therapeutic strategies. This study
Autor:
Satoru Noda, Tamami Morisaki, Yukio Miki, Naoyoshi Onoda, Tsutomu Takashima, Akitoshi Shimazaki, Daiju Ueda, Takashi Honjo, Shinichiro Kashiwagi, Akira Yamamoto
Publikováno v:
JCO Precision Oncology. :543-551
PURPOSE The molecular subtype of breast cancer is an important component of establishing the appropriate treatment strategy. In clinical practice, molecular subtypes are determined by receptor expressions. In this study, we developed a model using de